Diabetic Med: NHS糖尿病预防计划:转诊病人,接收和参与者特征

2018-10-23 MedSci MedSci原创

近日,国际杂志 《Diabetic Med》上在线发表一项关于更健康的你进展:NHS糖尿病预防计划:转诊病人,接收和参与者特征的研究。 研究目的是描述更健康的你早期进展:即NHS糖尿病预防计划,旨在预防或延迟已被确定为高风险的英格兰人中2型糖尿病发病的行为干预,评估方案提供者收到的转诊病人数和参加初次评估的比例,并确定与就诊率有关的因素。这些分析调查了2016年6月至2017年3月期间收到的

近日,国际杂志 《Diabetic Med》上在线发表一项关于更健康的你进展:NHS糖尿病预防计划:转诊病人,接收和参与者特征的研究。

研究目的是描述更健康的你早期进展:即NHS糖尿病预防计划,旨在预防或延迟已被确定为高风险的英格兰人中2糖尿病发病的行为干预,评估方案提供者收到的转诊病人数和参加初次评估的比例,并确定与就诊率有关的因素。这些分析调查了20166月至20173月期间收到的推荐数据。

研究期间共收到43 603个转诊,比预期高出16%。在这些人中,49%参加了初步评估,高于模拟评估的40%。在这些人中,性别没有显著差异(P = 0.061);然而,每10万人口的就诊率因性别,年龄组别,种族和贫困程度而有很大差异; 男性(P <0.001)显著降低(P <0.001),亚洲人、非裔加勒比人、混血儿和其他种族人群与白人欧洲人群相比,随着年龄增加而增加(P <0.001; P <0.001。种族和贫困与就诊率之间存在显著的相互作用(P <0.001),亚洲、非裔加勒比、混血和其他种族群体中最大贫困的五分之一人群与最小贫困的五分之一人群的就诊率显著提高,但对于欧洲白人种族群体而言,就诊率没有显著性差异。

分析表明,本研究的转诊人数和接收百分比超过先前的建模值。参与者的特征表明,该计划正在接触那些患上2型糖尿病的风险更高但通常无法有效获得医疗保健的人。

原始出处:

E. Barron R, Clark R,Hewingset al. Progress of the Healthier You: NHS Diabetes Prevention Programme: referrals, uptake and participant characteristics

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648609, encodeId=d57516486097e, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Wed Sep 04 15:08:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970609, encodeId=f9a219e060920, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 23 18:08:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045479, encodeId=960820454e919, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 03:08:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760816, encodeId=b2901e6081635, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Sep 21 01:08:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638773, encodeId=834e1638e739b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 04 02:08:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515269, encodeId=a4e01515269a6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609210, encodeId=d1021609210f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041933, encodeId=f2ce104193346, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 23 19:08:00 CST 2018, time=2018-10-23, status=1, ipAttribution=)]
    2019-09-04 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1648609, encodeId=d57516486097e, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Wed Sep 04 15:08:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970609, encodeId=f9a219e060920, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 23 18:08:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045479, encodeId=960820454e919, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 03:08:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760816, encodeId=b2901e6081635, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Sep 21 01:08:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638773, encodeId=834e1638e739b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 04 02:08:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515269, encodeId=a4e01515269a6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609210, encodeId=d1021609210f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041933, encodeId=f2ce104193346, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 23 19:08:00 CST 2018, time=2018-10-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1648609, encodeId=d57516486097e, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Wed Sep 04 15:08:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970609, encodeId=f9a219e060920, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 23 18:08:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045479, encodeId=960820454e919, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 03:08:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760816, encodeId=b2901e6081635, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Sep 21 01:08:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638773, encodeId=834e1638e739b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 04 02:08:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515269, encodeId=a4e01515269a6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609210, encodeId=d1021609210f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041933, encodeId=f2ce104193346, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 23 19:08:00 CST 2018, time=2018-10-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1648609, encodeId=d57516486097e, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Wed Sep 04 15:08:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970609, encodeId=f9a219e060920, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 23 18:08:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045479, encodeId=960820454e919, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 03:08:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760816, encodeId=b2901e6081635, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Sep 21 01:08:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638773, encodeId=834e1638e739b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 04 02:08:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515269, encodeId=a4e01515269a6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609210, encodeId=d1021609210f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041933, encodeId=f2ce104193346, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 23 19:08:00 CST 2018, time=2018-10-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1648609, encodeId=d57516486097e, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Wed Sep 04 15:08:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970609, encodeId=f9a219e060920, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 23 18:08:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045479, encodeId=960820454e919, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 03:08:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760816, encodeId=b2901e6081635, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Sep 21 01:08:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638773, encodeId=834e1638e739b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 04 02:08:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515269, encodeId=a4e01515269a6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609210, encodeId=d1021609210f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041933, encodeId=f2ce104193346, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 23 19:08:00 CST 2018, time=2018-10-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1648609, encodeId=d57516486097e, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Wed Sep 04 15:08:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970609, encodeId=f9a219e060920, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 23 18:08:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045479, encodeId=960820454e919, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 03:08:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760816, encodeId=b2901e6081635, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Sep 21 01:08:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638773, encodeId=834e1638e739b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 04 02:08:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515269, encodeId=a4e01515269a6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609210, encodeId=d1021609210f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041933, encodeId=f2ce104193346, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 23 19:08:00 CST 2018, time=2018-10-23, status=1, ipAttribution=)]
    2018-10-25 小几洁
  7. [GetPortalCommentsPageByObjectIdResponse(id=1648609, encodeId=d57516486097e, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Wed Sep 04 15:08:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970609, encodeId=f9a219e060920, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 23 18:08:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045479, encodeId=960820454e919, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 03:08:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760816, encodeId=b2901e6081635, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Sep 21 01:08:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638773, encodeId=834e1638e739b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 04 02:08:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515269, encodeId=a4e01515269a6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609210, encodeId=d1021609210f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041933, encodeId=f2ce104193346, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 23 19:08:00 CST 2018, time=2018-10-23, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1648609, encodeId=d57516486097e, content=<a href='/topic/show?id=afa493462ec' target=_blank style='color:#2F92EE;'>#转诊#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93462, encryptionId=afa493462ec, topicName=转诊)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=471123610769, createdName=kalseyzl, createdTime=Wed Sep 04 15:08:00 CST 2019, time=2019-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970609, encodeId=f9a219e060920, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Sun Dec 23 18:08:00 CST 2018, time=2018-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2045479, encodeId=960820454e919, content=<a href='/topic/show?id=a982e680663' target=_blank style='color:#2F92EE;'>#糖尿病预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76806, encryptionId=a982e680663, topicName=糖尿病预防)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Sat Jul 06 03:08:00 CST 2019, time=2019-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760816, encodeId=b2901e6081635, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sat Sep 21 01:08:00 CST 2019, time=2019-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1638773, encodeId=834e1638e739b, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Apr 04 02:08:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515269, encodeId=a4e01515269a6, content=<a href='/topic/show?id=402a12e83da' target=_blank style='color:#2F92EE;'>#NHS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12783, encryptionId=402a12e83da, topicName=NHS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=626110750337, createdName=小几洁, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609210, encodeId=d1021609210f8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Oct 25 07:08:00 CST 2018, time=2018-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041933, encodeId=f2ce104193346, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 23 19:08:00 CST 2018, time=2018-10-23, status=1, ipAttribution=)]
    2018-10-23 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

村医赔8万,主要因为疏忽了这两件事...

患者黄某于2018年3月3日下午独自到福建省洪塘镇某卫生所就诊,主诉头痛、失眠,卫生所陈医生给予2ml安痛定肌注,针后黄某称头疼缓解,自行回家后20分钟不慎摔倒,后脑着地致颅内大出血,送医抢救后现昏迷不醒。

妇科、产科、儿科常见病种入出院参考标准和转诊指导原则(试行)

本文中入院标准主要适用于有能力收治该病种患者的三级医院;转诊原则主要用于指导三级医院将经过治疗、病情稳定且未达到出院标准的患者,转入下一级医疗机构继续住院治疗;经医疗机构治疗后,病情稳定且不需要住院治疗的患者,医疗机构根据出院标准安排患者出院。

J Periodontol:2000-2015年澳大利亚牙周病的发展趋势

之前有研究调查了美国1980年至2000年期间牙周病严重程度与转诊专科护理的差异。本研究发现,2000年的患者牙周病的严重程度比20年前的高。

向卫生院转诊,村医有话说!

“叶医生,你这个月的上转病人只有2个。从一月份到八月份你总共才上转了21个人,离考核目标还有不小的差距!要注意,否则年终考核要扣分的!”卫生院的一位领导在辖区内的村医工作会议上说。

安徽三甲医院年内都将建医联体 上下级转诊仅收一次门槛费

8月28日,记者从安徽省卫生计生委了解到,根据日前出台的《关于推进医疗联合体建设的指导意见(征求意见稿)》(下称《意见》),今年安徽全省所有三甲医院至少组建1个符合自身专业特点的医疗联合体。届时,安徽省居民在医联体签约就医可享受若干就医优惠,如每年享受一次免费的专家健康咨询。同时,上级医院根据社区签约的常见病、多发病情况,将不少于5%的相应专科的专家号源投放到社区,供签约服务人群优先使用。医联体组

不鼓励家庭医生转诊患者? 英国分级诊疗误区值得警惕

家庭医生向大医院转诊患者,这是实现分级诊疗的一个重要环节。在英国,这一机制早已建立,但最近这种自下而上的转诊却让其整个医疗体系不堪重负,甚至出台规定:若家庭医生成功阻止患者到大医院就医,可获得“现金奖励”。这种 “利益共享”计划受到患者群体的强烈谴责。每减少一位转诊患者可获5英镑奖励目前已有四分之一英国国家医疗服务体系(National Health Service, NHS)引入财政激励措